Nonacog beta pegol is named as an intervention in 2 current clinical trials in our UK register. None are recruiting at the moment. All registered phases are Observational. The lead sponsor is Novo Nordisk A/S. The most-studied condition is Haemophilia B.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Adverse Event Data Collection From External Registries on Nonacog Beta Pegol
NCT03690336 · ClinicalTrials.gov ↗ · Haemophilia B
|
Observational | By invitation | Novo Nordisk A/S | UK |
|
A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN
NCT03745924 · ClinicalTrials.gov ↗ · Haemophilia B
|
Observational | By invitation | Novo Nordisk A/S | UK |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
4 single-substance products containing Nonacog beta pegol on the HPRA medicines list.
No entry for Nonacog beta pegol in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Novo Nordisk A/S | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in UK | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our UK register name Nonacog beta pegol as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Novo Nordisk A/S. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 4 single-substance products containing Nonacog beta pegol, for example Refixia 1 000 IU powder and solvent for solution for injection (Novo Nordisk A/S). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Nonacog beta pegol has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Nonacog beta pegol works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nonacog beta pegol works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nonacog beta pegol (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.